Pilot study to evaluate if contrast-enhanced ultrasound (CEUS) can predict treatment response in triple negative breast cancer (TNBC) patients receiving combined chemotherapy and Immune Checkpoint Inhibitors (ICI).
Objective
Primary Objective: 1. To determine whether early (during cycle 1-3) CEUS metrics can predict treatment response to systemic chemo/ICI therapy on gold standard CT/MR/PET imaging at 3-4 months. Secondary Objectives: 1. Evaluate the best CEUS technique to assess treatment response. 2. Whether the change in CEUS metrics (AUC and peak enhancement) predicts pathologic complete response at surgical excision. 3. Correlation of CEUS response with overall survival.
